SHL GM Frank Isaksson signs second LOI to further increase investments in Taiwan

TAOYUAN, Taiwan - Oct. 2, 2013 - PRLog -- SHL Group, the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices, signed a second Letter of Intent (LOI) with the Taiwan Ministry of Economic Affairs to invest an additional $40 million USD in Taiwan. This is a follow-up investment to the initial LOI signed in 2008 for a $100 million USD investment over five years, which was fulfilled within just four years. SHL now has over 2,500 employees globally, with 2,000 in Taiwan.

To ensure the company can provide a suite of high-quality, scalable manufacturing services to the rapidly growing drug delivery industry, SHL continues to enhance expertise and capacity in molding, material handling, assembly, tooling and automation. Production is ramping up at several facilities to further increase output for international biopharmaceutical customers. In addition, SHL is looking into expanding new services such as final assembly, packaging and labeling for customers and is expected to make additional investments in the near future.

Commenting on the company’s new LOI, General Manager Frank Isaksson stated, “It is once again our honor to commit to further investments in Taiwan. Thanks to some excellent planning, we have been able to expand rapidly without any interruption to production.  With the total global injectable drug delivery technologies market expected to reach an estimated $43 billion USD by 2017, we are determined to continue our investment and expansion plans in Taiwan.”

Frank Isaksson continues “Aside from expanding facilities and employing talented staff, SHL has also been investing heavily in high quality molding machines and other equipment for key capabilities such as tooling, molding, assembly, metrology and automation. SHL wants to ensure additional capacity will always be available in order to adapt to increasing customer demands. When working with SHL, the drug company can feel 100 % assured that we have the capacity to always deliver on time.”

About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices such as auto injectors and pen injectors. We have over 2,500 staff globally, with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.

Our organization consists of several distinct group companies:

SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
SHL Pharma
Provides final assembly, labeling and packaging services of drug delivery devices to the pharmaceutical and biotechnology industries

For additional information visit www.shl-group.com or contact us at info@shl-group.com

SHL Media Contact
Steven R. Kaufman
Marketing Director
+886 32170303
pr@shl-group.com